Document is current
Any future updates will be listed below
-
Authors
Liao, Jia
Qiu, Miaohan
Feng, Xiaojian
Chen, Kui
Zhang, Dingbao
Zou, Yuncheng
Zheng, Xiaohui
Zhao, Gang
Tian, Nailiang
Zheng, Zeqi
Peng, Xiaoping
Yang, Qing
Liang, Zhenyang
Li, Yi
Han, Yaling
Stone, Gregg W.
- License Information
-
More Information
Article History
Received: 1 April 2024
Accepted: 22 August 2024
First Online: 27 September 2024
Declarations
:
: The trial was approved by the ethics committee at the General Hospital of Northern Theater Command (Shengyang, China) (NO. k-2018–3). The study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was provided by all patients or their legal representatives before random assignment.
: Not applicable.
: Dr. Stone has received speaker honoraria from Medtronic, Pulnovo, Abiomed, Amgen, Boehringer Ingelheim; has served as a consultant to Abbott, Daiichi Sankyo, Ablative Solutions, CorFlow, Cardiomech, Robocath, Miracor, Vectorious, Apollo Therapeutics, Elucid Bio, Cardiac Success, Valfix, TherOx, HeartFlow, Neovasc, Ancora, Occlutech, Impulse Dynamics, Adona Medical, Millennia Biopharma, Oxitope, HighLife, Elixir, Remote Cardiac Enablement, Aria; and has equity/options from Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter. Dr. Stone’s employer, Mount Sinai Hospital, receives research grants from Shockwave, Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Vascular Dynamics, Pulnovo, V-wave and PCORI (via Weill Cornell Medical Center). The other authors declare that they have no potential competing interests.
